POPULARITY
6 episodes with Omics
9 episodes with Omics
4 episodes with Omics
6 episodes with Omics
8 episodes with Omics
2 episodes with Omics
5 episodes with Omics
4 episodes with Omics
3 episodes with Omics
Elo Life Systems: https://elolife.com/Super excited to bring on Matt DiLeo of ELO Life Systems on today's episode. Some of you may remember that ELO Life CEO Todd Rands was a part of 412 of this podcast two years ago. I've been fascinated by their work ever since to bring to the market what they call molecular farming. Matt does a great job of explaining the concept and how this shifts the value in some ways from food processors back to the farm by allowing farmers to grow desirable healthy ingredients inside of the commodity crops they already grow. It's kinda mind blowing. Some background on Matt: Dr. Matt DiLeo serves as the vice president of research & development at Elo Life Systems. In his role, Matt applies agricultural OMICs and precision breeding technologies to advance Elo's product pipeline. Prior to joining Elo, Matt held scientific leadership roles at Novozymes and KeyGene USA. Matt received his Ph.D. in Plant Pathology from UC Davis and completed a postdoc at the Boyce Thompson Institute, where he studied the impact of silencing regulatory genes on the nutritional composition of the tomato fruit metabolome.Matt seems to have a knack for being on the cutting edge of ag science and technology and has shown this in a variety of areas throughout his career.
The European Commission published its roadmap for phasing out animal testing on 1 June 2026, and the first meeting of ECHA's Collaborative Platform on Alternatives to Animal Testing has now taken place.In this episode, we explore what these developments mean for regulators, researchers and industry. Tomasz Sobanski from ECHA explains how new approach methodologies (NAMs) are moving from research into regulatory use, and why the transition requires more than replacing individual tests.The discussion looks at how the EU roadmap is expected to drive implementation across legislation, and how ECHA contributes through scientific and regulatory expertise, international cooperation and the collaborative platform.The episode features perspectives from the EPAA, PETA and HEAL on regulatory acceptance, confidence-building, animal welfare, and maintaining a high level of protection for human health and the environment.Useful linksECHA convenes first meeting of its collaborative platform on alternatives to animal testingECHA supports EU roadmap for alternatives to animal testing with new collaborative platformRoadmap towards phasing out animal testing and related materialsGive us feedback**************Subscribe to our YouTube channelSubscribe to our Safer Chemicals PodcastSubscribe to our newsFollow us on:XLinkedInFacebookInstagramBlueSkyVisit our website Disclaimer: Views expressed by interviewees do not necessarily represent the official position of the European Chemicals Agency. All content is up to date at the time of publication.Hosted on Ausha. See ausha.co/privacy-policy for more information.
The following article of the Entrepreneurs industry is: 'AI x Multi-omics: From Molecular Chaos to Predictive Cancer Care' by Luis Velez, CEO & Founder, Theranomics.
Send us Fan MailDigiPath Digest #45 asks a practical question: can AI in pathology move from correlation to real clinical use? In this episode, I review four papers that push on that question from different angles: computational pathology moving toward morphology-driven molecular inference, the current state of digital cytopathology and AI, multi-omics and precision oncology in hepatocellular carcinoma, and AI literacy in veterinary education. What ties them together is not model performance alone. It is the harder question of validation, workflow fit, quantitative use, ethics, and human oversight.In the first paper, I talk about computational pathology as more than pattern recognition. The focus is on morphology-driven molecular inference, digital biomarkers, and why spatial omics matters as biological ground truth. I also discuss why continuous quantitative scoring is more useful than forcing biology into rough scoring buckets. The second paper focuses on digital cytopathology. Cytology was early for FDA-cleared AI in cervical screening, but non-gynecologic cytology is still much harder to digitize because of specimen variability and workflow complexity. I also cover telecytology, rapid onsite evaluation, automation, and quality control. The third paper looks at hepatocellular carcinoma and AI-driven precision oncology. This part is about using AI and machine learning to integrate genomics, transcriptomics, proteomics, metabolomics, radiomics, and pathology to support biomarker discovery, tumor microenvironment analysis, and treatment stratification. The fourth paper may be the most broadly useful. It proposes an AI literacy curriculum for veterinary education that covers AI fundamentals, machine learning evaluation, LLMs, ethics, liability, and academic integrity. I think that matters far beyond veterinary medicine, because if clinicians are expected to use AI tools responsibly, AI literacy cannot stay optional. Highlights 00:01 Welcome and overview of the four papers 03:02 Computational pathology and morphology-driven molecular inference 11:01 Digital cytopathology, telecytology, and QC 20:47 AI/ML in hepatocellular carcinoma precision oncology 31:04 AI literacy in veterinary education 47:42 Final takeaways and Digital Pathology 101 update ResourcesComputational Pathology as a Mechanistic Discipline: From Morphology to Molecular Data https://pubmed.ncbi.nlm.nih.gov/42052846/Advances in Digital Cytopathology and Artificial Intelligence Applications https://pubmed.ncbi.nlm.nih.gov/42046894/Navigating the Labyrinth of Hepatocellular Carcinoma: Leveraging AI/ML for Precision Oncology https://pubmed.ncbi.nlm.nih.gov/42065059/Curriculum Framework for Artificial Intelligence Literacy in Veterinary Education Front Vet Sci. 2026;13:1801756 Support the showGet the "Digital Pathology 101" FREE E-book and join us!
BUFFALO, NY — May 7, 2026 — A new #research paper was #published in Volume 18 of Aging-US on April 24, 2026, titled “The BHARAT study: a multi-modal, multi-omics investigation of aging signatures in the Indian population.” The study was led by first author Suramya Asthana and corresponding author Deepak Kumar Saini from the Indian Institute of Science (IISc). The authors introduce the BHARAT Study (Biomarkers of Healthy Aging, Resilience, Adversity, and Transitions), India's first large-scale, discovery-driven multi-omics cohort focused on understanding biological aging in the Indian population. The initiative was developed to address a major gap in aging research, as most existing biological age models and aging datasets have been derived primarily from Western populations. The BHARAT study is a multi-center, cross-sectional observational cohort that integrates clinical, molecular, lifestyle, and environmental data from participants across diverse demographic groups in India. The initiative aims to enroll healthy volunteers spanning multiple age groups, with balanced rural-urban and sex representation. Biological samples—including blood, urine, stool, cheek swabs, and hair—will undergo extensive multi-omics profiling, including epigenomics, proteomics, metabolomics, lipidomics, metagenomics, and immune phenotyping. “By generating interoperable, high-resolution data suited for mechanistic modelling and machine learning, BHARAT contributes a resource of global relevance that would be capable of refining universal models of aging biology while revealing novel, population-specific pathways that inform prevention and intervention strategies.” The initiative uses a hub-and-spoke framework centered at the Indian Institute of Science, which serves as the central hub for biobanking, multi-omics analysis, computational integration, and AI-driven modeling. Clinical and community partners across India contribute participant recruitment, clinical assessments, and biological sampling, enabling the study to capture the country's extraordinary genetic, environmental, dietary, and socioeconomic diversity. A major focus of the study is the development of population-specific biological aging signatures and predictive models tailored to Indian populations. Researchers aim to identify biomarkers associated with resilience, frailty, and age-related decline while also recalibrating biological clocks that may not accurately reflect aging trajectories in non-Western populations. The study further seeks to establish standardized reference datasets and create scalable infrastructure for future longitudinal aging research in India. Importantly, the BHARAT study combines untargeted discovery-based omics technologies with advanced artificial intelligence and machine learning approaches. By integrating molecular data with clinical and lifestyle information, the initiative aims to improve understanding of how biological aging is shaped by genetics, environment, nutrition, infection burden, and social determinants of health. Overall, this study establishes a comprehensive framework for aging research in one of the world's most diverse populations. By generating large-scale, population-specific biological datasets, the BHARAT initiative may help advance precision aging research, improve risk prediction models, and support the development of more personalized approaches to healthy aging and disease prevention. DOI - https://doi.org/10.18632/aging.206373 Corresponding author - Deepak Kumar Saini - deepaksaini@iisc.ac.in Abstract video - https://www.youtube.com/watch?v=qH2AbitDURQ Website - https://www.Aging-US.com MEDIA@IMPACTJOURNALS.COM
Send us Fan MailPaper Discussed in this Episode:Spatial omics and AI for clinically actionable cancer biomarkers. Reitsam NG. PLoS Med 2026; 23(4): e1005049.Episode Summary: In this deep dive, we explore how artificial intelligence and spatial omics are fundamentally rewriting the rules of cancer diagnostics. We break down a 2026 editorial that challenges a deceptively simple question driving modern oncology: Is a tumor "positive" or "negative" for a biomarker? As targeted cancer therapies evolve, this binary thinking is failing us. We discuss why mapping where and how much of a therapeutic target exists is crucial, and how AI is stepping in to solve the reproducibility issues human pathologists face when making borderline diagnostic calls.In This Episode, We Cover:• The Illusion of "Positive" vs. "Negative": Why the basic premise of modern cancer therapies—like antibody-drug conjugates (ADCs)—often falls apart in reality when we ignore the spatial heterogeneity of a tumor.• The Power of Computational Pathology: How AI is transforming subjective, qualitative estimates into continuous, reproducible data, scaling the quantification of complex biomarkers like PD-L1 and TROP2.• "Virtual" Proteomics: The fascinating concept of using AI models to infer high-dimensional spatial information and immune maps directly from standard, routine H&E stained slides.• The HER2 Bottleneck: A real-world look at the breast cancer drug T-DXd, which now demands pathologists distinguish between "HER2-low" and "HER2-ultralow". While human agreement drops below 70% at these fuzzy decision boundaries, AI steps up with a staggering ~97% sensitivity.• Three Shifts for the Future: Why clinical trials and routines must adopt continuous measures (like percentage of expressing cells), demand longitudinal repeat testing at disease progression, and utilize adaptive trial platforms.• Bridging the Gap to Reality: The massive hurdles preventing widespread adoption—such as equipment costs exceeding $250,000 and massive data storage needs. We discuss why a hybrid workflow that bolsters routine pathology with deployable AI is the best path forward to prevent widening global health disparities.Key Takeaway: The future of precision oncology isn't just about finding new drug targets; it's about fundamentally changing how we measure them. By moving away from rigid binary thresholds and using AI to map the continuous, spatial reality of tumors, we can unlock the true potential of targeted therapies. However, achieving this diagnostic ecosystem requires overcoming significant financial and systemic hurdles—such as updating reimbursement pathways and proficiency testing—to ensure these life-saving insights are accessible across all healthcare settings.Support the showGet the "Digital Pathology 101" FREE E-book and join us!
Send us Fan MailPaper Discussed in this Episode: Advancements in bone marrow biopsy: the role of omics and artificial intelligence in hematologic diagnostics. Maryam Alwahaibi and Nasar Alwahaibi. Front. Med. 2026; 13:1772478.Episode Summary: In this journal club deep dive, we explore a paradigm shift in hematopathology, moving from 19th-century visual assessments to the cutting edge of precision medicine. We examine a 2026 review that unpacks how combining artificial intelligence with multi-omics technologies is transforming the traditional bone marrow biopsy from a static, subjective snapshot into a live, interactive, predictive 3D map. We ask: What happens when deep learning can predict underlying genetic mutations just by analyzing the visual shape and texture of a cell?.In This Episode, We Cover:The Breaking Point of Traditional Diagnostics: Why the 150-year-old gold standard of H&E staining and human visual assessment is hitting a biological and operational wall, plagued by subjectivity, high variability, and observer fatigue.The Multi-Omics Multiverse: Moving beyond standard genomics to unpack the complex biological machinery of the marrow, including:Epigenomics: The biological "switches," like DNA methylation, that control cell fate and can kick off malignant transformation without altering the underlying DNA sequence.Lipidomics: How cellular fats form specialized signaling rafts that actively remodel the marrow's communication network.Microbiomics (The Gut-Marrow Axis): How systemic inflammation driven by gut dysbiosis acts like a massive "traffic jam" that indirectly disrupts local bone marrow homeostasis and blood cell production.AI as the Ultimate Analytical Partner: How artificial intelligence serves as a bridge between physical tissue morphology and high-dimensional molecular data. We discuss AI tools like MarrowQuant for objective cellularity mapping and the Continuous Index of Fibrosis (CIF) that replaces clunky human guesswork with a granular, predictive metric.Predicting Genotype from Phenotype: The revolutionary capability of deep learning models to predict underlying genetic mutations (like TET2 or del 5q MDS) purely from the subvisual, spatial arrangement and shape of cells on a standard slide.Roadblocks and Solutions: Why this technology isn't universally adopted yet. We break down the "black box" problem of AI, the brittleness of algorithms in different clinical settings, and how innovations like Federated Learning and Explainable AI (using heat maps) are overcoming these hurdles.Key Takeaway: The integration of AI and multi-omics is redefining our understanding of bone marrow diseases. By uncovering invisible molecular machinery and objectively translating it through transparent algorithms, we are moving away from subjective human bottlenecks toward a highly personalized, predictive model of hematologic care.Support the showGet the "Digital Pathology 101" FREE E-book and join us!
Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data.Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics, a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery.Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single-cell annotation. In a world abounding in AI hype, Parashar helps us cut through the noise and point out paths to data driven success.01:00 Meet Parashar Dhapola05:45 AI in biopharma09:29 AI automation vs. new capabilities11:28 What makes single-cell omics data different18:46 Risks of incorrect cell annotation34:37 Future of single-cell analyticsThis episode is produced with the support of Nygen Analytics. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: CyteType - AI powered cell type annotationBehind the Cure51 deal: Is NVIDIA becoming biotech's AI infrastructure?The past, present, and future of genome sequencing
An international consortium of researchers is leading a global initiative to map gene expression in wheat using spatial omics technology. This effort aims to increase wheat production by 60% to meet the demands of a projected global population of 9.8 billion by 2050. Spatial omics technologies offer precision in genomics research by mapping gene activity at the cellular level, surpassing traditional methods. The consortium proposes a multi-omics approach and highlights the role of artificial intelligence in analyzing complex datasets. Challenges include preparing plant tissue samples and the scarcity of wheat-specific antibodies, with proposed solutions like adopting medical imaging techniques. The initiative seeks to build a comprehensive spatial omics atlas to benefit the wheat community and address challenges posed by climate change and emerging diseases.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.
Drs. Petri and Woolfson discuss a simple risk score using autoantibodies, complement, and demographics to predict which SLE patients are most likely to develop proteinuria and lupus nephritis. They also highlight evidence showing that earlier kidney biopsies at lower proteinuria levels, especially in patients with low complement, can detect serious disease sooner and improve outcomes.
Send us Fan MailPaper Discussed in this AI Journal Club: "Transforming Gastric Biopsy Diagnostics: Integrating Omics Technologies and Artificial Intelligence" by Nasar Alwahaibi, published in the journal Biomedicines.Episode Summary: In this episode, we explore how traditional gastric biopsies are getting a massive, sci-fi-level upgrade. For over a century, diagnostic practice has relied heavily on visual pattern recognition via histomorphology—essentially looking at stained tissue under a brightfield microscope. Today, we discuss the paradigm shift toward data-driven "precision gastroenterology," made possible by merging high-resolution multi-omics technologies with the computational power of artificial intelligence (AI).Key Topics Covered:The Limits of the Status Quo: Traditional microscopic evaluation is foundational but limited. It suffers from interobserver variability (human disagreement), sampling limitations, and an inability to fully capture a tumor's biological complexity or predict how a disease will progress and respond to treatment.The Multi-Omics Revolution: Moving beyond basic static genomics to include transcriptomics, epigenomics, proteomics, and metabolomics provides a comprehensive map of cellular activity—what we call the "active construction site". We highlight a pivotal study by Kamio et al., which demonstrated that knowing a patient's specific TP53 mutation profile (such as the R175H mutation) in early-onset gastric cancer can predict a significantly longer time-to-treatment failure (17.3 months vs. 7.0 months) using oxaliplatin chemotherapy.AI as the Medical Co-Pilot: Deep learning models and convolutional neural networks (CNNs) are transforming both endoscopy and histopathology. For example, an AI-assisted tandem study showed a reduction in gastric neoplasm miss rates from 27.3% to an incredible 6.1%. Furthermore, AI tools have demonstrated the ability to outperform human experts in objectively scoring gastritis severity. However, it is crucial to remember that AI is currently a decision-support tool that still requires human oversight, especially in complex clinical realities.The "Endo-Histo-Omics" Paradigm: We dive into the future of integrated diagnostics, such as the HTML (Highly Trustworthy Multi-omics Learning) framework. This self-adaptive model dynamically tailors its computational architecture to prioritize the most reliable data from a specific sample's unique multi-omics and visual profile.Real-World Roadblocks: Before this becomes the standard of care at your local clinic, the medical field must overcome four main pillars of limitations: AI hurdles (data annotation burdens, black-box models), omics constraints (high costs, tiny biopsy sizes), integration complexity (lack of standardized software frameworks), and ethical/regulatory challenges (data privacy, algorithmic bias, and accountability).Conclusion: The traditional intuition of the pathologist is evolving as we transition toward personalized, multi-omics management. Keep questioning the data, exploring the mechanics of the science, and we will see you on the next episode!Support the showGet the "Digital Pathology 101" FREE E-book and join us!
In this episode of Longevity by Design, host Dr. Gil Blander sits down with Dr. Nathan Price, Professor and Co-Director at the Buck Institute for Research on Aging. Together, they explore how systems biology, artificial intelligence, and deep health data are changing the way we approach aging and prevention. Nathan explains why looking at single biomarkers falls short and why a network view of biology gives a clearer path to understanding disease and resilience.Nathan shares how new tools, like genetics, proteomics, and the emerging field of digital twins, can help predict disease risk years in advance and guide more effective, personalized interventions. He also discusses how integrating data from wearables, blood tests, and the microbiome can help people move from reactive medicine to proactive health decisions, allowing for interventions that fit the individual.The conversation highlights the promise and practical limits of current technologies, the trade-offs involved in optimizing health, and the power of AI to accelerate both research and personal health journeys. Nathan makes a strong case for the unique biology each person brings to the table and shows how the tools available today can help anyone take charge of their own healthspan in ways not possible before.Guest-at-a-Glance
Host Parag Mallick chats with Professor Afshin Beheshti who is a Professor of Surgery, Director of the Center for Space Biomedicine, and Associate Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. In addition, Professor Beheshti has a visiting researcher appointment at the Broad Institute of MIT and Harvard and is president of two non-profits – the COVID-19 International Research Team and Kwaai. The latter aims to democratize access to artificial intelligence through the design, construction, and maintenance of a free personal AI called Kwaai.Professor Beheshti's research covers a range of topics focused on how circulating mirco RNAs and mitochondria impact health, but this conversation focuses primarily on Professor Beheshti's work advancing our understanding of how spaceflight impacts biology. We cover:How research on spaceflight and biology is doneGaps that remain in our understanding of spaceflight and biologyOmics studies of spaceflight and biologyHow studying spaceflight and biology enhances our understanding of human health more broadlyResourcesTrivedi Institute for Space and Global BiomedicineNew Institute at the University of Pittsburgh focused on “advancing human health through space-driven innovation”NASA Open Science Data Repository"Provides open access to biological and physical science datasets from spaceflight and ground studies, enabling data reuse for discovery and innovation."Camera et al., 2024. Agining and putative frailty biomarkers are altered by spaceflightStudy on molecular biomarkers and frailty phenotypes in spaceOverbey et al., 2024. The Space Omics and Medical Atlas (SOMA) and international astronaut biobankAn “integrated data and sample repository for clinical, cellular, and multi-omic research profiles” from a variety of space missionsSpace Omics and Medical Atlas (SOMA) websiteCorti et al., 2024. To boldly go where no microRNAs have gone before: spaceflight impact on risk for small-for-gestational-age infantsExplores how miRNA signatures of “small-for-gestational-age” are impacted by the space environmentBeheshti et al., 2013. Age and space irradiation modulate tumor progression: implications for carcinogenesis riskSome of Professor Beheshti's early...
In this episode of The Poultry Nutrition Blackbelt Podcast, Dr. Rana Waqar Tabish from Auburn University breaks down how multi-omics is being applied to practical poultry nutrition challenges. He explains how transcriptomics and microbiome data clarify gut health responses to calcium levels, limestone particle size, and fiber strategies under necrotic enteritis and coccidiosis pressure. The discussion connects molecular pathways with intestinal integrity, immune regulation, and performance outcomes in commercial broilers. Listen now on all major platforms."The multi-omics help explain the molecular background behind productivity changes that traditional performance data alone cannot clearly describe."Meet the guest: Dr. Rana Waqar Tabish is a poultry researcher and veterinarian at Auburn University specializing in multi-omics, gut health, and precision nutrition in broilers. His work integrates transcriptomics and microbiome profiling to understand intestinal integrity and immune responses under enteric disease challenges.Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:53) Introduction(02:51) Omics overview(05:08) Disease models(06:21) Fiber effects(08:00) Calcium levels(09:53) Particle size(13:31) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like:* Fortiva* Kemin- Poultry Science Association- Anitox- DietForge
In this episode of the Epigenetics Podcast, we talked with Will Wang from Sanford Burnham Prebys about his work on muscle stem cell repair, regeneration, and aging, exploring spatial-omics and machine learning. We begin our conversation by exploring the traditional concepts of spatial biology and how they have evolved to play a critical role in disease research. Dr. Wang recounts his journey from a young student in a family of academics to becoming a leading figure in regenerative biology, highlighting how his early interests in life sciences, natural problem-solving abilities, and inspirations from mentorship set the stage for his current research trajectory. Throughout the discussion, we uncover key insights on how muscle stem cells transition from a quiescent state to a proliferative state in response to injury and how this dynamic process is governed by the epigenetic landscape and various signalling pathways. Dr. Wang emphasises the impact of external factors—be it microenvironment conditions or metabolic cues—on the fate and function of these stem cells, reflecting on the methodologies used to investigate these processes throughout his career. He shares fascinating findings from his PhD work, where he explored the regulatory role of transcription factors like PAX-7 in muscle stem cell activation, and how subsequent research developed in his postdoc at Stanford further illuminated the relationship between metabolism and histone acetylation. This pivotal work not only demonstrated how metabolic states dictate epigenetic modifications but also offered potential therapeutic insights for muscle degeneration and repair. As we move into more recent projects, Dr. Wang discusses the advances in multiplexed spatial proteomics and the insights garnered from a single-cell spatiotemporal atlas of muscle regeneration, which highlight the cellular heterogeneity in muscle tissue. He describes the use of novel computational tools, including neural networks, to uncover the regulatory mechanisms underlying stem cell function, particularly how prostaglandin signalling informs the regeneration process and how age impacts stem cell efficacy. The episode then wraps up with an engaging dialogue about the future implications of Dr. Wang's work in addressing age-related muscle degradation and broader applications in regenerative medicine. References Yucel, N., Wang, Y. X., Mai, T., Porpiglia, E., Lund, P. J., Markov, G., Garcia, B. A., Bendall, S. C., Angelo, M., & Blau, H. M. (2019). Glucose Metabolism Drives Histone Acetylation Landscape Transitions that Dictate Muscle Stem Cell Function. Cell Reports, 27(13), 3939-3955.e6. https://doi.org/10.1016/j.celrep.2019.05.092 Wang, Y. X., Palla, A. R., Ho, A. T. V., Robinson, D. C. L., Ravichandran, M., Markov, G. J., Mai, T., Still, C., Balsubramani, A., Nair, S., Holbrook, C. A., Yang, A. V., Kraft, P. E., Su, S., Burns, D. M., Yucel, N. D., Qi, L. S., Kundaje, A., & Blau, H. M. (2025). Multiomic profiling reveals that prostaglandin E2 reverses aged muscle stem cell dysfunction, leading to increased regeneration and strength. Cell Stem Cell, 32(7), 1154-1169.e9. https://doi.org/10.1016/j.stem.2025.05.012 Related Episodes Stem Cell Transcriptional Regulation in Naive vs. Primed Pluripotency (Christa Buecker) The Effect of Mechanotransduction on Chromatin Structure and Transcription in Stem Cells (Sara Wickström) Epigenetic Regulation of Stem Cell Self-Renewal and Differentiation (Peggy Goodell) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com
In this episode of the Epigenetics Podcast, we talked with Will Wang from Sanford Burnham Prebys about his work on muscle stem cell repair, regeneration, and aging, exploring spatial-omics and machine learning. We begin our conversation by exploring the traditional concepts of spatial biology and how they have evolved to play a critical role in disease research. Dr. Wang recounts his journey from a young student in a family of academics to becoming a leading figure in regenerative biology, highlighting how his early interests in life sciences, natural problem-solving abilities, and inspirations from mentorship set the stage for his current research trajectory. Throughout the discussion, we uncover key insights on how muscle stem cells transition from a quiescent state to a proliferative state in response to injury and how this dynamic process is governed by the epigenetic landscape and various signalling pathways. Dr. Wang emphasises the impact of external factors—be it microenvironment conditions or metabolic cues—on the fate and function of these stem cells, reflecting on the methodologies used to investigate these processes throughout his career. He shares fascinating findings from his PhD work, where he explored the regulatory role of transcription factors like PAC-7 in muscle stem cell activation, and how subsequent research developed in his postdoc at Stanford further illuminated the relationship between metabolism and histone acetylation. This pivotal work not only demonstrated how metabolic states dictate epigenetic modifications but also offered potential therapeutic insights for muscle degeneration and repair. As we move into more recent projects, Dr. Wang discusses the advances in multiplexed spatial proteomics and the insights garnered from a single-cell spatiotemporal atlas of muscle regeneration, which highlight the cellular heterogeneity in muscle tissue. He describes the use of novel computational tools, including neural networks, to uncover the regulatory mechanisms underlying stem cell function, particularly how prostaglandin signalling informs the regeneration process and how age impacts stem cell efficacy. The episode then wraps up with an engaging dialogue about the future implications of Dr. Wang's work in addressing age-related muscle degradation and broader applications in regenerative medicine. References Yucel, N., Wang, Y. X., Mai, T., Porpiglia, E., Lund, P. J., Markov, G., Garcia, B. A., Bendall, S. C., Angelo, M., & Blau, H. M. (2019). Glucose Metabolism Drives Histone Acetylation Landscape Transitions that Dictate Muscle Stem Cell Function. Cell Reports, 27(13), 3939-3955.e6. https://doi.org/10.1016/j.celrep.2019.05.092 Wang, Y. X., Palla, A. R., Ho, A. T. V., Robinson, D. C. L., Ravichandran, M., Markov, G. J., Mai, T., Still, C., Balsubramani, A., Nair, S., Holbrook, C. A., Yang, A. V., Kraft, P. E., Su, S., Burns, D. M., Yucel, N. D., Qi, L. S., Kundaje, A., & Blau, H. M. (2025). Multiomic profiling reveals that prostaglandin E2 reverses aged muscle stem cell dysfunction, leading to increased regeneration and strength. Cell Stem Cell, 32(7), 1154-1169.e9. https://doi.org/10.1016/j.stem.2025.05.012 Related Episodes Stem Cell Transcriptional Regulation in Naive vs. Primed Pluripotency (Christa Buecker) The Effect of Mechanotransduction on Chromatin Structure and Transcription in Stem Cells (Sara Wickström) Epigenetic Regulation of Stem Cell Self-Renewal and Differentiation (Peggy Goodell) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com
Because of our strong capabilities in training and technical assistance, ORAU was contracted by the National Institutes of Health to develop a state-of-the-art training center for users of the Common Fund Data Ecosystem. This ecosystem is an infrastructure to make data from the NIH's various programs easier to access with the aim of facilitating improved discovery, reuse, integration, and analyses of these datasets to form novel hypothesis for accelerating discoveries in biomedical research. In this episode of Further Together, Allissa Dillman, Ph.D., co-principal investigator and owner of BioData Sage LLC, and Jennifer Burnette, ORAU project director, talk to host Michael Holtz about the importance of the CFDE Training Center and how it can help researchers mine data for omics research of various kinds. Dillman also hosts the Decoding the Data Ecosystem Podcast, which dives deep into unraveling the complexities and exploring the depths of omics data. The podcast can be found here: https://blubrry.com/3847772/ Check out the Common Fund Data Ecosystem Training Center here: https://orau.org/cfde-trainingcenter/index.html Find the Common Fund Data Ecosystem here: https://commonfund.nih.gov/dataecosystem
In this episode of Longevity by Design, Dr. Gil Blander welcomes Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging. Eric discusses the science behind therapeutic plasma exchange (TPE) and its potential to slow biological aging in humans. The conversation explores findings from a recent clinical trial, including measurable age reversal using epigenetic clocks.Eric explains how removing and replacing plasma can dilute pro-aging factors in the blood, a concept inspired by earlier animal studies on parabiosis. He also describes why rigorous, placebo-controlled human trials are crucial for validating longevity interventions and distinguishing the field from hype-driven wellness trends.The episode also highlights how omics data, such as metabolomics and proteomics, are shaping a new era of precision aging research. Eric emphasizes the value of lifestyle interventions as a foundation and sees future opportunities in combining TPE with personalized strategies to extend healthspan. Guest-at-a-Glance
Marni Jacobs, Ph.D., M.P.H., presents the MOM Health Study, part of the NIH's Multi-Omics for Health and Disease (MOHD) Consortium, which investigates hypertensive disorders of pregnancy—such as preeclampsia—and their impact on postpartum health. The study aims to uncover the biological mechanisms linking these conditions to long-term maternal outcomes like stroke and heart disease. Unlike other disease sites, participants are enrolled before outcomes are known, allowing researchers to track 750 pregnancies through delivery and one year postpartum. Data collection includes surveys, biospecimens, placental tissue, and continuous blood pressure monitoring. By integrating clinical, environmental, and molecular data, the study supports early detection strategies and collaborative research to improve maternal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40671]
Marni Jacobs, Ph.D., M.P.H., presents the MOM Health Study, part of the NIH's Multi-Omics for Health and Disease (MOHD) Consortium, which investigates hypertensive disorders of pregnancy—such as preeclampsia—and their impact on postpartum health. The study aims to uncover the biological mechanisms linking these conditions to long-term maternal outcomes like stroke and heart disease. Unlike other disease sites, participants are enrolled before outcomes are known, allowing researchers to track 750 pregnancies through delivery and one year postpartum. Data collection includes surveys, biospecimens, placental tissue, and continuous blood pressure monitoring. By integrating clinical, environmental, and molecular data, the study supports early detection strategies and collaborative research to improve maternal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40671]
Marni Jacobs, Ph.D., M.P.H., presents the MOM Health Study, part of the NIH's Multi-Omics for Health and Disease (MOHD) Consortium, which investigates hypertensive disorders of pregnancy—such as preeclampsia—and their impact on postpartum health. The study aims to uncover the biological mechanisms linking these conditions to long-term maternal outcomes like stroke and heart disease. Unlike other disease sites, participants are enrolled before outcomes are known, allowing researchers to track 750 pregnancies through delivery and one year postpartum. Data collection includes surveys, biospecimens, placental tissue, and continuous blood pressure monitoring. By integrating clinical, environmental, and molecular data, the study supports early detection strategies and collaborative research to improve maternal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40671]
Marni Jacobs, Ph.D., M.P.H., presents the MOM Health Study, part of the NIH's Multi-Omics for Health and Disease (MOHD) Consortium, which investigates hypertensive disorders of pregnancy—such as preeclampsia—and their impact on postpartum health. The study aims to uncover the biological mechanisms linking these conditions to long-term maternal outcomes like stroke and heart disease. Unlike other disease sites, participants are enrolled before outcomes are known, allowing researchers to track 750 pregnancies through delivery and one year postpartum. Data collection includes surveys, biospecimens, placental tissue, and continuous blood pressure monitoring. By integrating clinical, environmental, and molecular data, the study supports early detection strategies and collaborative research to improve maternal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40671]
Marni Jacobs, Ph.D., M.P.H., presents the MOM Health Study, part of the NIH's Multi-Omics for Health and Disease (MOHD) Consortium, which investigates hypertensive disorders of pregnancy—such as preeclampsia—and their impact on postpartum health. The study aims to uncover the biological mechanisms linking these conditions to long-term maternal outcomes like stroke and heart disease. Unlike other disease sites, participants are enrolled before outcomes are known, allowing researchers to track 750 pregnancies through delivery and one year postpartum. Data collection includes surveys, biospecimens, placental tissue, and continuous blood pressure monitoring. By integrating clinical, environmental, and molecular data, the study supports early detection strategies and collaborative research to improve maternal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40671]
Marni Jacobs, Ph.D., M.P.H., presents the MOM Health Study, part of the NIH's Multi-Omics for Health and Disease (MOHD) Consortium, which investigates hypertensive disorders of pregnancy—such as preeclampsia—and their impact on postpartum health. The study aims to uncover the biological mechanisms linking these conditions to long-term maternal outcomes like stroke and heart disease. Unlike other disease sites, participants are enrolled before outcomes are known, allowing researchers to track 750 pregnancies through delivery and one year postpartum. Data collection includes surveys, biospecimens, placental tissue, and continuous blood pressure monitoring. By integrating clinical, environmental, and molecular data, the study supports early detection strategies and collaborative research to improve maternal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40671]
Marni Jacobs, Ph.D., M.P.H., presents the MOM Health Study, part of the NIH's Multi-Omics for Health and Disease (MOHD) Consortium, which investigates hypertensive disorders of pregnancy—such as preeclampsia—and their impact on postpartum health. The study aims to uncover the biological mechanisms linking these conditions to long-term maternal outcomes like stroke and heart disease. Unlike other disease sites, participants are enrolled before outcomes are known, allowing researchers to track 750 pregnancies through delivery and one year postpartum. Data collection includes surveys, biospecimens, placental tissue, and continuous blood pressure monitoring. By integrating clinical, environmental, and molecular data, the study supports early detection strategies and collaborative research to improve maternal health. Series: "Motherhood Channel" [Health and Medicine] [Show ID: 40671]
For years, disease diagnosis and treatment have focused on a few biomarkers, overlooking thousands of vital biological signals. Despite biotech advances, most therapies are still based on limited data, missing countless breakthroughs.Multiomics changes that. By analyzing tens of thousands of proteins, metabolites, and lipids, it reveals hidden insights, paving the way for smarter, faster, and more effective medical discoveries.In this must-listen episode, David Brühlmann welcomes Mo Jain, founder and CSO of Sapient, a pioneering force in bringing multiomic platforms out of academia and into the heart of drug development. A physician-scientist by training and a visionary entrepreneur by choice, Mo's journey spans decades at the cutting edge of analytical technologies, culminating in the creation of ultra-high-throughput systems that analyze up to 20,000 biomarkers in a single run for real-world impact.Here are three reasons why this episode needs to be on your playlist:Multiomics at Scale: Mo shares how his team at Sapient turbocharged mass spectrometry, enabling simultaneous measurement of thousands of molecules, transforming routine diagnostics and making previously unimaginable insights accessible to scientists everywhere.Turning Data into Action: Generating vast data is only half the battle. Mo explains how Sapient developed advanced biocomputational teams and frameworks to extract actionable answers, guiding drug developers to faster, smarter decisions and helping avoid the pitfalls that cripple so many omics projects.The Future Is Personalized and Sooner Than You Think: From dramatically earlier disease detection to truly personalized therapies, Mo paints an optimistic picture of a coming era where AI, multiomics, and new therapeutic modalities rapidly accelerate both discovery and delivery, reshaping how biotech companies tackle even the toughest diseases.Ready to break out of the 20-biomarker rut and see what 20,000 data points can reveal? Tune in to discover how you can harness multiomics in your own research and hear Mo's advice for scientists and entrepreneurs venturing beyond the bench.Connect with Mo Jain:LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895baWebsite: www.sapient.bioCompany LinkedIn Page: https://www.linkedin.com/company/sapientbioNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechSupport the show
What if the secret to truly personalized precision medicine lies not in your genetic code, but in your zip code?For years, biotech has focused on genomics to explain disease and drug response, but DNA only accounts for a fraction of the story. The real breakthrough? Multi-omics: the large-scale analysis of proteins, metabolites, and lipids, powered by advanced mass spectrometry and AI, offering a fuller picture of human health.In this episode, David Brühlmann meets Mo Jain, founder and CSO of Sapient, a leader in multi-omics analytics. With over two decades of experience across physiology, biomedicine, and computational biology, Mo has been at the forefront of developing scalable multi-omics technologies that are changing the way we predict, diagnose, and treat disease. From leading an academic lab to building a pioneering biotech company, Mo's journey reflects a passion for uncovering the hidden 80–90% of disease risk that lies beyond our genes.Here are three reasons you'll want to listen to this episode:Your Environment Matters More Than Your Genes: Mo explains why your zip code is a stronger predictor of your health than your genetic code, challenging the industry's long-held beliefs and opening new avenues for disease prevention and risk assessment.Multi-omics Disrupts Drug Development: Discover how integrating thousands of biological data points can revolutionize drug discovery by identifying novel targets, better predicting drug response, and accelerating therapeutic breakthroughs that were previously out of reach.Big Data Finally Becomes Actionable: Thanks to rapid advances in mass spectrometry and computational power, scientists can now make sense of overwhelming volumes of multi-omic data, turning what was once information overload into actionable insights for diagnostics and drug development.Ready to think beyond your genes? The biotech revolution is here, and it starts in your neighborhood.Connect with Mo Jain:LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895baWebsite: www.sapient.bioCompany LinkedIn Page: https://www.linkedin.com/company/sapientbioNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechSupport the show
In this episode of The Poultry Nutrition Blackbelt Podcast, Dr. Lisa Bielke from North Carolina State University talks about how probiotics, prebiotics, and phytogenics are changing the way we think about poultry health. She shares how tools like omics and machine learning are helping us better understand the gut microbiome, vertical transmission, and how birds recover from disease. Get a closer look at where poultry health is headed. Listen now on all major platforms!"I've seen big changes in where things are going—prebiotics, synbiotics, phytobiotics—we're getting better at using them and understanding how they work."Meet the guest: Dr. Lisa Bielke holds a Ph.D. and M.S. in Poultry Science from the University of Arkansas and a B.S. from Texas A&M University. She currently serves as the Distinguished Scholar and Prestage Endowed Chair of Turkey Health Research at North Carolina State University. Her work centers on microbiology, omics technologies, and improving gut health in poultry.Liked this one? Don't stop now — Here's what we think you'll love!Dr. Ryan Arsenault: Gut Health in Poultry | Ep. 46Dr. JT Pope: Innovative Feed Systems | Ep. 50Dr. Wilmer Pacheco: Multi-Carbohydrase Enzyme for Poultry | Ep. 82What you'll learn:(00:00) Highlight(01:22) Introduction(02:32) Evolving nutritional strategies(04:24) Omics in poultry health(05:43) Manipulating microbiomes(06:36) Targeted outcomes(11:18) Big picture outlook(14:28) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like:* Kerry* Kemin- Poultry Science Association- Anitox- BASF
BUFFALO, NY — June 12, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 5, on May 3, 2025, titled “APOE genotype and biological age impact inter-omic associations related to bioenergetics.” In this study, led by first author Dylan Ellis and corresponding author Noa Rappaport from the Institute for Systems Biology, researchers discovered that different versions of the APOE gene—particularly ε2 and ε4—are linked to metabolic patterns associated with aging and Alzheimer's disease risk. Both variants were linked to increased levels of diacylglycerols, a type of fat molecule connected to insulin resistance and inflammation, suggesting shared disruptions in how the body regulates energy. The research team analyzed data from over 2,200 adults without an Alzheimer's diagnosis, exploring how APOE genotypes influence biological age, a measure of health that reflects how quickly or slowly someone is aging at a cellular level. They found that the same metabolic disturbances seen in ε2 carriers were also present in people considered biologically older, revealing unexpected overlap between genetic risk and aging-related metabolic changes. To examine these connections in more detail, the researchers used a multi-omics approach, combining blood-based metabolism and protein data, gut bacteria analysis from stool samples, and clinical chemistry data. This method allowed them to map how genetic differences and biological aging affect the body's energy systems. They observed altered connections between glucose metabolism, inflammatory markers, and key molecules that play roles in energy production, indicating early disruptions that could contribute to age-related diseases. One of the study's surprising findings was that the ε2 variant, usually associated with longer life and reduced Alzheimer's risk, showed metabolic traits similar to those found in insulin-resistant individuals. This suggests that ε2 may carry metabolic disadvantages earlier in life, with its protective effects becoming more pronounced later. Conversely, ε4—linked to greater Alzheimer's risk—may exert its influence based on interactions with lifestyle factors like diet, sex, and overall health status. “‘Omics association patterns of ε2-carriers and increased biological age were also counter-intuitively similar, displaying significantly increased associations between insulin resistance markers and energy-generating pathway metabolites.” By identifying these shared biological signatures, this study offers a new framework for understanding how genes and metabolism work together to influence aging. These findings could support more personalized health strategies aimed at delaying biological aging and reducing the risk of chronic diseases. As aging populations grow worldwide, understanding these pathways is essential to improving healthspan. DOI - https://doi.org/10.18632/aging.206243 Corresponding author - Noa Rappaport - noa.rappaport@isbscience.org Video short - https://www.youtube.com/watch?v=75hZQoO5U0U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206243 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, apolipoprotein E (APOE), biological age, metabolism, Alzheimer's disease (AD), insulin resistance To learn more about the journal, please visit our website at https://www.Aging-US.com and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Morgan Cheatham joins hosts Raj Manrai and Andy Beam on NEJM AI Grand Rounds to discuss the evolving landscape of artificial intelligence in health care, from its role in automating clinical documentation to its transformative potential in genomic medicine. A venture capitalist and future physician, Morgan shares how his background in computational decision sciences led him to medical school and investing, offering insights into how AI is reshaping everything from disease phenotyping and clinical decision-making to scaling precision medicine. He reflects on his work evaluating ChatGPT's performance on the USMLE, the growing importance of genomic learning health systems, and why the biggest challenge isn't technological innovation—but aligning payment models to support AI-driven advancements in medicine. Transcript.
Osteosarcoma Webinar Series: Sowmya Ramesh, PhD joins us on OsteoBites to discuss how multi-modal omics analysis identifies targetable sensory neuron circuitry that promotes sarcoma disease progression.Bone pain is a hallmark of bone cancers, including osteosarcoma (OS), mediated by skeletal-innervating peripheral afferent neurons. However, the roles of tumor-associated sensory neurons in OS beyond pain perception remain poorly understood. To investigate their regulatory functions, a chemical-genetic approach was employed in mice carrying a knock-in allele for TrkA to perturb sensory nerve innervation during OS growth and progression. TrkA inhibition in these transgenic mice significantly reduced sarcoma-associated sensory innervation and vascularization, altered tumor-associated macrophage polarization, decreased tumor growth and metastasis, and extended overall survival.These findings suggest that targeting pathological innervation in OS may serve as an adjunctive therapy to enhance clinical outcomes and survival.Dr. Ramesh is a postdoctoral researcher from the James lab at Johns Hopkins. The lab's research focus lies at the intersection of skeletal pathophysiology and stem cell biology. The lab looks at the interaction of nerves in various musculoskeletal repair including bone repair and regeneration, osteoprogenitor cell characterization, and neoplastic bone. Dr. Ramesh specifically works on understanding how peripheral nerves regulate osteosarcoma disease progression.
In this insightful episode, I sit down with Andrea Nakayama, a Functional Medicine Nutritionist and educator who has revolutionized how we approach chronic illness. Andrea shares her personal story of resilience after losing her young husband to a brain tumor and how it inspired her to become a leader in Functional Nutrition.We dive into the gaps in Functional Medicine, why chronic illness is at epidemic levels, and Andrea's unique framework for addressing root causes. She explains the pitfalls of overtesting, the importance of bio-individuality, and how to build a therapeutic partnership that empowers clients and practitioners alike. Whether you're navigating your own health journey or supporting others, this conversation is packed with wisdom, practical advice, and inspiration.Key Topics Covered:1.Andrea's Journey: How personal tragedy led Andrea to Functional Nutrition and a mission to transform lives.2.The Chronic Illness Epidemic: Why so many people are underserved by conventional and Functional Medicine approaches.3.Root Cause Methodology: Andrea's systems biology approach and how it addresses the complexity of chronic illness.4.Testing in Functional Medicine: The dangers of overtesting and how to focus on what really matters.5.Personalized Nutrition: How bio-individuality and the science of Omics can guide health transformations.6.Empowering Partnerships: The importance of collaboration between patients, practitioners, and doctors.Memorable Quotes:•“True healing happens when we look beyond symptoms and focus on the whole person.”•“Bio-individuality reminds us that no two health journeys are the same.”•“Chronic illness doesn't have to feel overwhelming when we have the right tools and partnerships.”Connect with Andrea Nakayama:•Website: Functional Nutrition Alliance•Podcast: 15-Minute Matrix•Instagram: @andreanakayamaResources Mentioned in the Episode:•Functional Nutrition Alliance Training Programs•Articles and resources on bio-individuality and root cause healingConnect with Me:•Instagram: @codyjeansanders•Learn more about Mixhers: www.mixhers.comDon't Forget:If you enjoyed this episode, please subscribe, leave a review, and share it with a friend! Your support helps us bring more empowering conversations to your ears.Did you learn something new today? Be sure to subscribe to this podcast and share this episode with all the girls you love. We would appreciate it if you'd also leave us a rating and review on iTunes.Want to join our Mixhers Girl community and keep this conversation going? We'd love to hear your thoughts, feelings and experiences! Join us HERE!Join Mixhers email list and be the first to have access to new products and be the girl in the know!Follow Cody Instagram:@codyjeansanders
ศาสตร์ ‘Omics' เป็นศาสตร์ที่มีบทบาทสำคัญในการทำความเข้าใจกลไกของร่างกายมนุษย์ในภาพรวม โดยไม่ได้มุ่งเน้นเพียงส่วนใดส่วนหนึ่ง แต่ครอบคลุมทั้งระบบร่างกายมนุษย์ เพื่อค้นหาสาเหตุของการเกิดโรคและความผิดปกติทางพันธุกรรมในระดับลึก นำไปสู่การพัฒนาวิธีการรักษาที่มีความแม่นยำและเฉพาะเจาะจงมากขึ้น นอกจากนี้ศาสตร์ Omics ยังเปิดโอกาสทางธุรกิจที่น่าจับตามองในอุตสาหกรรม BioTech โดยเฉพาะในกลุ่มยารักษาโรคมะเร็ง ซึ่งเป็นหนึ่งในผลิตภัณฑ์ที่ใช้งบประมาณวิจัยและพัฒนาสูงที่สุดในบริษัทยาชั้นนำระดับโลก คำถามคือ ประเทศไทยที่โดดเด่นด้านการแพทย์จะคว้าโอกาสนี้อย่างไร Secret Science ชวนพูดคุยกับ ศ. นพ.มานพ พิทักษ์ภากร อาจารย์ประจำสาขาวิชาเวชพันธุศาสตร์ ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ศิริราชพยาบาล มหาวิทยาลัยมหิดล ติดตามได้ในเอพิโสดนี้
Jeremy Forman joins us to open up about the hurdles– and successes that come with building data products for pharmaceutical companies. Although he's new to Pfizer, Jeremy has years of experience leading data teams at organizations like Seagen and the Bill and Melinda Gates Foundation. He currently serves in a more specialized role in Pfizer's R&D department, building AI and analytical data products for scientists and researchers. . Jeremy gave us a good luck at his team makeup, and in particular, how his data product analysts and UX designers work with pharmaceutical scientists and domain experts to build data-driven solutions.. We talked a good deal about how and when UX design plays a role in Pfizer's data products, including a GenAI-based application they recently launched internally. Highlights/ Skip to: (1:26) Jeremy's background in analytics and transition into working for Pfizer (2:42) Building an effective AI analytics and data team for pharma R&D (5:20) How Pfizer finds data products managers (8:03) Jeremy's philosophy behind building data products and how he adapts it to Pfizer (12:32) The moment Jeremy heard a Pfizer end-user use product management research language and why it mattered (13:55) How Jeremy's technical team members work with UX designers (18:00) The challenges that come with producing data products in the medical field (23:02) How to justify spending the budget on UX design for data products (24:59) The results we've seen having UX design work on AI / GenAI products (25:53) What Jeremy learned at the Bill & Melinda Gates Foundation with regards to UX and its impact on him now (28:22) Managing the "rough dance" between data science and UX (33:22) Breaking down Jeremy's GenAI application demo from CDIOQ (36:02) What would Jeremy prioritize right now if his team got additional funding (38:48) Advice Jeremy would have given himself 10 years ago (40:46) Where you can find more from Jeremy Quotes from Today's Episode “We have stream-aligned squads focused on specific areas such as regulatory, safety and quality, or oncology research. That's so we can create functional career pathing and limit context switching and fragmentation. They can become experts in their particular area and build a culture within that small team. It's difficult to build good [pharma] data products. You need to understand the domain you're supporting. You can't take somebody with a financial background and put them in an Omics situation. It just doesn't work. And we have a lot of the scars, and the failures to prove that.” - Jeremy Forman (4:12) “You have to have the product mindset to deliver the value and the promise of AI data analytics. I think small, independent, autonomous, empowered squads with a product leader is the only way that you can iterate fast enough with [pharma data products].” - Jeremy Forman (8:46) “The biggest challenge is when we say data products. It means a lot of different things to a lot of different people, and it's difficult to articulate what a data product is. Is it a view in a database? Is it a table? Is it a query? We're all talking about it in different terms, and nobody's actually delivering data products.” - Jeremy Forman (10:53) “I think when we're talking about [data products] there's some type of data asset that has value to an end-user, versus a report or an algorithm. I think it's even hard for UX people to really understand how to think about an actual data product. I think it's hard for people to conceptualize, how do we do design around that? It's one of the areas I think I've seen the biggest challenges, and I think some of the areas we've learned the most. If you build a data product, it's not accurate, and people are getting results that are incomplete… people will abandon it quickly.” - Jeremy Forman (15:56) “ I think that UX design and AI development or data science work is a magical partnership, but they often don't know how to work with each other. That's been a challenge, but I think investing in that has been critical to us. Even though we've had struggles… I think we've also done a good job of understanding the [user] experience and impact that we want to have. The prototype we shared [at CDIOQ] is driven by user experience and trying to get information in the hands of the research organization to understand some portfolio types of decisions that have been made in the past. And it's been really successful.” - Jeremy Forman (24:59) “If you're having technology conversations with your business users, and you're focused only the technology output, you're just building reports. [After adopting If we're having technology conversations with our business users and only focused on the technology output, we're just building reports. [After we adopted a human-centered design approach], it was talking [with end-users] about outcomes, value, and adoption. Having that resource transformed the conversation, and I felt like our quality went up. I felt like our output went down, but our impact went up. [End-users] loved the tools, and that wasn't what was happening before… I credit a lot of that to the human-centered design team.” - Jeremy Forman (26:39) “When you're thinking about automation through machine learning or building algorithms for [clinical trial analysis], it becomes a harder dance between data scientists and human-centered design. I think there's a lack of appreciation and understanding of what UX can do. Human-centered design is an empathy-driven understanding of users' experience, their work, their workflow, and the challenges they have. I don't think there's an appreciation of that skill set.” - Jeremy Forman (29:20) “Are people excited about it? Is there value? Are we hearing positive things? Do they want us to continue? That's really how I've been judging success. Is it saving people time, and do they want to continue to use it? They want to continue to invest in it. They want to take their time as end-users, to help with testing, helping to refine it. Those are the indicators. We're not generating revenue, so what does the adoption look like? Are people excited about it? Are they telling friends? Do they want more? When I hear that the ten people [who were initial users] are happy and that they think it should be rolled out to the whole broader audience, I think that's a good sign.” - Jeremy Forman (35:19) Links Referenced LinkedIn: https://www.linkedin.com/in/jeremy-forman-6b982710/
Dive into the cutting-edge world of cancer research and precision medicine with Dr. Wahid Awad, CEO and Founder of Rosetta Omics. In this episode, we explore how spatial multiomics and AI are revolutionizing cancer treatment. Dr. Awad shares his journey from Egypt to founding a biotech startup in France, and discusses the challenges and opportunities in the field of personalized medicine. Learn about the latest advancements in cancer diagnostics, the role of AI in biotechnology, and how global perspectives are shaping the future of healthcare. Whether you're a science enthusiast, healthcare professional, or simply curious about the future of medicine, this episode offers valuable insights into the forefront of cancer research and biotechnology innovation. In this episode of Life Science Success, host Don interviews Waheed Awad, CEO and founder of Rosetta Omics. Waheed shares his inspiring journey from Egypt to founding his deep-tech biotech startup in France, focusing on precision medicine and cancer research. Listen in to discover Waheed's innovative use of spatial multiomics and AI, his personal motivation stemming from his father's battle with cancer, and his global experiences shaping his entrepreneurial path. Sponsored by D3 Digital Media Marketing, tune in for an engaging conversation about the future of cancer treatment and personalized medicine. 00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message: D3 Digital Media Marketing 01:22 Guest Introduction: Waheed Awad 03:06 Waheed's Journey from Egypt to France 08:30 Founding Rosetta Omics 10:10 Personal Connection to Cancer Research 15:25 Global Experiences Shaping Biotechnology 24:06 Rosetta Omics: Precision Medicine and AI 31:16 Balancing Roles and Responsibilities 39:50 Challenges and Inspirations 49:09 Conclusion and Final Thoughts
BUFFALO, NY- August 21, 2024 – A new #editorial was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 15 on August 8, 2024, entitled, “The benefits of exercise on aging: focus on muscle biomarkers.” The focus on maintaining health and vitality (e.g., good healthspan) in later life has become increasingly important as the world's population ages. Over the past few decades, groundbreaking research in the field of aging has deepened our understanding of the molecular basis of this process. In the last decade, advances in aging research have identified biomarkers such as DNA methylation (DNAm) and gene expression, offering insights into both chronological and biological aging. Researchers Robin Grolaux, Bernadette Jones-Freeman, Macsue Jacques, and Nir Eynon from the Australian Regenerative Medicine Institute at Monash University in Melbourne, explore the impact of exercise on these biomarkers in human skeletal muscle—a critical tissue for metabolism, thermogenesis, and movement—revealing its potential to foster healthier aging. This study represents the first quantitative and qualitative analysis of the effects of exercise on age-related biomarkers in human skeletal tissues. Future research could explore the global effects of exercise on various molecular pathways and differentiate between exercise types to develop more effective personalized therapies. “We have the opportunity to uncover functional therapies that effectively impact aging.” DOI - https://doi.org/10.18632/aging.206064 Corresponding Author - Nir Eynon - nir.eynon@monash.edu Video short - https://www.youtube.com/watch?v=Dhiq2I0sW1U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206064 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, skeletal muscle, exercise, epigenetics, OMICs, biomarkers About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Part 3 of 4. My guest for this week's episode is Noam Solomon, CEO and co-founder at Immunai, a pioneering biotech company that is comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes.
Multi-omics is the layering of genetic information (genomics) with laboratory biomarker results (metabolomics) to understand the root cause of disease and risk. This educational series focuses on genetic variants in specific enzymes and explains how to evaluate the systemic effects. Today's episode revolves around the enzyme cystathionine-beta-synthase (CBS). This enzyme is important for homocysteine metabolism, sitting at a branch point between two important cycles: methylation and transsulfuration. The action of this enzyme is important for balancing the critical functions of methylation with the creation of glutathione and energy. Listen to understand why this enzyme is important and what a genetic variant in CBS might mean for you and your patients. Today on The Lab Report: 2:20 Reminder of what we mean by multi-omics 4:50 Introducing the CBS enzyme and the sink drain metaphor 7:40 The genetics of CBS – the silent mutation – and its potential effects 12:40 Better Know A Biomarker: Cystathionine! 16:20 Activators and inhibitors of CBS and its effects on other biomarkers 18:55 Question of the Day: Does a CBS SNP cause elevated ammonia levels? 21:40 Evaluating surrounding biomarkers and how do you treat this SNP? Additional Resources: Methylation Panel Genova Connect **PROMO CODE TheLabReport20 for 20% off your purchase** Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week's episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don't forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. To find a qualified healthcare provider to connect you with Genova testing, or to access select products directly yourself, visit Genova Connect. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and show not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests.See omnystudio.com/listener for privacy information.
What's the buzz in omics all about and how can it help you make better beer? Special Guests: Glen Fox, Harmonie Bettenhausen, and Laura Burns.
Guang Li, PhD, researcher at UPMC Children's Hospital of Pittsburgh discusses his research on the developing heart with the hope of one day preventing congenital heart defects.
Have you ever wondered if there was a way to gain deep insights into your body's unique needs and optimize your health? The answer may lie in the cutting-edge field of metabolomics. In today's episode of the Longevity Podcast, Dr. Paniz Jasbi, the co-founder of Theriome, and I discuss how their groundbreaking Aristotle test is revolutionizing the way we approach health and wellness. From assessing mitochondrial function and nutritional status to identifying potential disease risks and guiding personalized interventions, the Aristotle test is a game-changer for precision medicine. Overall, we discuss this test's ability to offer valuable insights for dealing with complex health issues, recovering from illness, or optimizing your athletic performance. Dr. Paniz Jasbi founded Theriome in 2022. Integrating the theory of –omics sciences, Theriome seeks to innovate personalized wellness by analyzing the totality of systems biology—from the genome to the metabolome, and everything in between. Use code NAT to save when ordering the Theriome metabolomic test for 10% off. Shop here: https://therio.me/ Thank you to our sponsors for making this episode possible: Vitali: Visit https://www.vitaliskincare.com/discount/Nathalie20 and use code Nathalie20 to save on your order. Mitopure: Use code NAT10 for 10% off your order at https://www.timelinenutrition.com/shop/nutrition Berkeley Life: Consumers may register and place an order using my code NIDDBL for 10% off at berkeleylife.com Find more from Dr. Paniz Jasbi: Website: https://therio.me/ Instagram: @theriometest Book: Theriome and the Aristotle Test Find more from Nathalie: YouTube: https://www.youtube.com/channel/UCmholC48MqRC50UffIZOMOQ Join Nat's Membership Community: https://www.natniddam.com/bsp-community Sign up for Nats Newsletter: https://landing.mailerlite.com/webforms/landing/i7d5m0 Instagram: https://www.instagram.com/nathalieniddam/ Website: www.NatNiddam.com Facebook Group: https://www.facebook.com/groups/biohackingsuperhumanperformance What We Discuss: 04:30 Understanding the Omics 09:58 Leveraging AI in Metabolomics 19:25 The Microbiome and ILIA Test 23:35 Exploring Spermidine and Other Metabolites 45:41 The Importance of Directly Assessing Mitochondrial Function 50:08 The Implications of Disease Enrichment Analysis 52:56 The Importance of Access to Personal Health Information 01:07:24 The Accessibility and Affordability of the Test
BUFFALO, NY- July 9, 2024 – A new #editorial paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 12, entitled, “Aging retinal pigmented epithelium: omics-based insights into vision decline.” In this new editorial, researchers Ioan V. Matei and Luminita Paraoan from Edge Hill University discuss vision decline with aging. Of all senses affected by aging, vision decline arguably has the most impactful relationship with overall wellbeing, health and personal autonomy. However, while the ensuing importance of vision loss has long been recognised from a public health perspective given an increasingly aging population, understanding the molecular and cellular mechanisms driving age-related pathological changes is still in its infancy. “This matter is, therefore, critical for tackling sensory impairment and ensuring healthy aging.” The retinal pigmented epithelium (RPE), the cellular monolayer located between the neuroretina and the highly vascularized choroid, from which it is separated by Bruch's membrane (BrM), has a critical role in human vision and performs essential functions throughout life for maintaining the retinal homeostasis. RPE is a specialised, fully differentiated tissue that is mitotically inactive, with no regenerative potential. Unsurprisingly, given all its characteristics, functions and metabolic demands, the RPE is particularly susceptible to aging, sustaining significant morphologic and physiologic changes. “Aging is recognised as the highest risk factor for age-related macular degeneration (AMD), the leading cause of adult visual impairment and blindness in the Northern Hemisphere, which is directly linked to specific pathological changes of the RPE located in the macula, i.e., the central part of retina; these changes, therefore, affect central vision required for reading, driving, and discerning details of pictures, faces, shapes and colors.” DOI - https://doi.org/10.18632/aging.205914 Corresponding author - Luminita Paraoan - Luminita.Paraoan@edgehill.ac.uk Video short - https://www.youtube.com/watch?v=_-zhhFjlQ4Y Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205914 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, RPE, vision, omics About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
After realizing at a young age that rock and roll might be a better hobby than a career, our guest chose chemistry and chromatography as his path, and he's rocked that career choice!In this fun and engaging conversation, you'll meet Frank Steiner, PhD, Senior Manager of Product Applications, and Scientific Advisor at Thermo Fisher Scientific, who has earned much respect for his contributions to the field of high-performance liquid chromatography (HPLC). He and his team are customer number one for new HPLC products and generate much of the data used to support product launches. Steeped in the theory and fundamentals of HPLC, they provide us with a very approachable summary of the technique and considerations that must be balanced across diverse applications. Follow Frank and Paolo as they uncover insights on the evolutionary arc of HPLC, what challenges still exist, and why Frank believes it to be the technique that is most widespread and effective in affecting our lives. As always, we promise to let you get to know Frank, his personal story, and some bits of sage advice from a man that's been there and done that. Related episodes: Season 1, Ep.3: There's chemistry is in the air!Season 1, Ep.7: Stronger magnets, stronger scienceSeason 4, Ep.7: From an F in chemistry to 40 years in chemicals Bonus content!Access bonus content curated by this episode's guest by visiting www.thermofisher.com/chemistry-podcast for links to recent publications, podcasts, books, videos and more.View the video version of this episode on www.thermofisher.com/chemistry-podcast. A free thank you gift for our listeners! Visit the episode website and request your free Bringing Chemistry to Life t shirtUse Podcast Code: 2023wrap in December 2023 or Ba++ery in January 2024 Share your feedback with us! Email helloBCTL@thermofisher.com About Your HostPaolo Braiuca grew up in the North-East of Italy and holds a PhD in Pharmaceutical Sciences from nearby esteemed University of Trieste, Italy. He developed expertise in biocatalysis during his years of post-doctoral research in Italy and the UK, where he co-founded a startup company. With this new venture, Paolo's career shifted from R&D to business development, taking on roles in commercial, product management, and marketing. He has worked in the specialty chemicals, biotechnology, and pharmaceutical markets in Germany and the UK, where he presently resides. He is currently the Director of Global Market Development in the Laboratory Chemicals Division at Thermo Fisher Scientific™ which put him in the host chair of the Bringing Chemistry to Life podcast. A busy father of four, in what little free time he has, you'll find him inventing electronic devices with the help of his loyal 3D-printer and soldering iron. And if you ask him, he'll call himself a “maker” at heart.
Commentary by Dr. Valentin Fuster
Root cause medicine is all the rage if you follow any functional medicine experts and while that is an important part of treating you as a whole, root causes are not the only thing we need to think about. My guest on this episode, functional nutritionist Andrea Nakayama, so beautifully talks about the roots but also the branches, the various systems and terrains of our body and lifestyles. She also shares the developing science of omics, the reason some of us react differently to foods, medicines, supplements, viruses, etc. than someone else. Andrea also shares much of her journey with her own health as well as the loss of her husband and how her experiences with autoimmunity and her husband's cancer have shaped the way she sees functional medicine and health. Learn more about Andrea's work here. To work with Dr Brooke click here and if you loved this episode please leave a review! Follow Dr Brooke on Instagram and get signed up for my awesome emails here. Seriously,I write really great emails, or so 1000s of women tell me and I'd like to send you one too. Be sure you connect with me in my FREE PRIVATE Facebook group: Hormones & Happiness with Dr Brooke where other amazing, like minded women like YOU are already hanging out! Join us! Partners of the Dr. Brooke Show (Stuff I Know You Will Love!) This episode is also sponsored by Organifi whose green juice is my absolute favorite on the market. It's certified USDA organic, contains 11 superfoods including the heavy hitters spirulina and matcha, includes 600mg of ashwaganda and is a great boost of antioxidants for better energy, less brain fog and better exercise recovery. And ladies, you're going to want to try Harmony! Their female hormone balancing blend of shatavari, maca and vitex in a delicious cacao base. Save 20% with code BETTEREVERYDAY at checkout. Aging is a part of life, but our cells don't always complete their normal life cycle so well due to a host of factors in our modern world. When cells don't go through a healthy life cycle process they become what are called “zombie cells” - nonfunctional and unhelpful but still sucking up resources from the healthy cells around them. This process of senolysis can be aided by key ingredients found in Neurohacker's amazing product: Qualia Senolytic. Clear out those dead cells and see your brain, skin and body come back alive. Save 50% off with this link and use code BETTEREVERYDAY at checkout for an additional 15% off! This is anti-aging at its core and you only need to take this a couple days of the month! And there is a money back guarantee, get yours here.
Dr. Bajnath is a Board-Certified Family Physician and author of The Longevity Equation: The Step-By-Step Blueprint to Hack Your Genes, Optimize Your Health, And Master the Art of Existence. His approach to medicine incorporates precision personalized healthcare modalities such as individualized nutrition, genomic medicine, advanced biomarker testing, microbiome analysis, and biometric lifestyle monitoring. In today's conversation we'll be exploring what omics are and how Dr. Bajnath uses precision medicine to create personalized treatment plans for his patients. We'll also talk about how he integrates this approach into his medical practice and what you can do to bring this level of care into your wellness plan. So, if you're curious about precision medicine and how it can improve your health, you definitely don't want to miss this episode.
Drink in the Style - AM950 The Progressive Voice of Minnesota
Guang Li, PhD, researcher at UPMC Children's Hospital of Pittsburgh discusses his research on the developing heart with the hope of one day preventing congenital heart defects.
In this month's episode of the American Blue Economy Podcast, host Rear Admiral Tim Gallaudet, PhD, US Navy (ret) explores the many benefits of biotechnology to the American Blue Economy, Drawing from his recent article in Real Clear Science, 7 Technologies Revolutionizing Our Understanding of the Ocean | RealClearScience, he is assisted by 4 of his former colleagues from the National Oceanic and Atmospheric Administration (NOAA). These exceptional experts include: Dr. Kelly Goodwin, ‘Omics lead for NOAA's Office of Oceanic and Atmospheric Research; Dr. Luke Thompson, Associate Research Professor with NOAA's Northern Gulf Institute at Mississippi State University and NOAA's Atlantic Oceanographic and Meteorologic Laboratory; Dr. Jeanette Davis, a Marine Microbiologist, bestselling author, and Policy Advisor to the Deputy Undersecretary at NOAA; and Dr. Krista Nichols, Genetics and Evolution Program Manager at NOAA's Northwest Fisheries Science Center and NOAA's Omics Working Group Vice Chair. Be ready to be marveled by the magnificent field of marine microbiology in the American Blue Economy!
While licking his waffle ice cream cone, Chairman Joe claims the economy is "strong as hell". The GOP plans for the FBI & Biden crime family. The Dem crime wave is turning voters to the GOP. The Pelosi Trump rap battle and MAGA Republicans perform well in their debates.Copyright Sean Casey All Rights Reserved
© 2020-2026 Ivy Podcast Discovery LLC
